Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and...

Background: Glatiramer acetate (GA) and interferon-beta (IFN-beta) are disease-modifying t http://t.co/K21ZxRdP2Z

via VAT ENGPlus Combo | VATPlus | MotionTrak http://t.co/K21ZxRdP2Z